Indication: Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)
Locally Advanced, Unresectable, Stage III
Sub-indication: Unresectable, Stage III NSCLC who have not progressed after cCRT.
Line of Therapy: Locally Advanced/Adjuvant
Principal Investigator: John Hamm, M.D.Norton Cancer Institute
Sponsor: MedImmune, LLC, subsidiary of AstraZeneca PLC
Email for more information: Lung-NCIResearch@nortonhealthcare.org